Salem, Mass. March 27th, 2020
Commonwealth Diagnostics International, Inc. (“CDI”) today announced their commitment to assist in the continuity of care for the millions of Gastrointestinal sufferers in the United States. The healthcare delivery system is being pushed to the brink of its capacity, and these times have brought with them a significantly heightened sense of unease in patient and provider communities. With the American College of Gastroenterology (ACG) , American Gastroenterology Association (AGA), American Association for the Study of Liver Diseases (AASLD), and the American Society for Gastrointestinal Endoscopy (ASGE) issuing a Joint GI Society Message on COVID-19 advising gastroenterologists across the country to “strongly consider rescheduling elective non-urgent procedures,” and all hospital resources devoted to addressing the COVID-19 patient influx, CDI wants to help the affected patient communities in any way we can.
In these times of unprecedented uncertainty, CDI is proud to offer a customer-centric, decentralized diagnostic service model that can help to ensure continuity of care for functional gastrointestinal sufferers and their Healthcare Providers across the country. Our CLIA-certified, FDA-registered, ISO 13485-certified laboratory and at-home diagnostic test kits allow patients to obtain critical diagnostic services while the healthcare delivery system continues to adapt to this destabilizing pandemic. It would be our honor to work with your hospitals, networks, providers or affiliated partners to ensure that our patients are still receiving the critical care they need during this time while alleviating the risk and burden of asking them to leave their homes in order to do so.
Our team at CDI is available to help all hospital and network providers across the United States to ensure continuity of care and quality diagnosis for patients suffering from non-urgent functional gastrointestinal disorders including Small Intestinal Bacterial Overgrowth (SIBO), Irritable Bowel Syndrome (IBS), and a multitude of carbohydrate malabsorption disorders. CDI offers at-home testing kits that are shipped directly to the patient’s residence with full Instructions for Use and Patient Videos available to assist the patient in the testing process. Once the test has been completed in the comfort and safety of the patient’s home, the patient simply returns the test kit back to CDI’s CLIA-Certified laboratory for analysis using the prepaid UPS or USPS shipping label included in each kit. Results are returned to the overseeing healthcare provider 1 business day following receipt of the test kit. CDI also maintains a full-time dedicated Customer Service team working to assist patients during this critical time [9:00am – 5:00pm EDT].
If you are a physician transitioning to tele-visits and a remote patient is experiencing SIBO symptoms, our tests can be ordered online (www.CommDx.com (http://www.commdx.com) ), drop shipped to your patients home, and results can be emailed or faxed within 24 hrs...enabling you, the physician, to get quick and accurate data to help direct meaningful health outcomes.
Any healthcare provider can simply place an order for the patient here: https://www.commdx.com/order-kits.php. No account setup or activation required. Some key components of our model are below:
We hope that our model assists the millions of patients afflicted with functional gastrointestinal disorders who may have limited or no access to diagnostic testing during this time due to the safety considerations and resource restrictions imposed on the healthcare system by this destabilizing pandemic.
If you have any questions after reading through these materials please reach out to our dedicated Customer Service Department via email at email@example.com or via telephone at (888) 258-5966 during normal business hours Monday-Friday.
We look forward to providing you and your patients with the important clinical data you need to drive healthcare decisions.
Craig S. Strasnick
President and CEO